Organization | Boston Scientific Corporation

Boston Scientific Corporation Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Marlborough MA United States (1979)

Status: No NME R&D (1979)

Organization Overview

First Clinical Trial

2005

NCT00129545

First Marketed Drug

1992

piroxicam (feldene)

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (5)

atenolol (tenormin) (1992)

carbidopa (sinemet) (1994)

haloperidol (haldol)

levodopa (larodopa) (1994)

piroxicam (feldene) (1992)

Drugs in Phase 4 Trials (14)

Key: Boston Scientific Corporation (7) Acquired (7)

acetylsalicylic acid (aspirin) (10 trials)

alteplase (Activase) (4 trials)

clopidogrel (plavix) (9 trials)

crotalidae polyvalent immune fab (ovine) (CroFab) (1 trial)

everolimus (zortress) (5 trials)

heparin (liquaemin) (3 trials)

polidocanol (asclera) (10 trials)

prasugrel (effient) (8 trials)

sirolimus (rapamune) (1 trial)

tenecteplase (tnkase) (1 trial)

ticagrelor (brilinta) (2 trials)

ticlopidine (ticlid) (1 trial)

umirolimus (Biolimus) (1 trial)

zotarolimus (1 trial)

Drugs in Phase 3 Trials (11)

Key: Boston Scientific Corporation (6) Acquired (5)

90-yttrium (3 trials)

bivalirudin (angiomax) (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

colchicine (colbenemid) (1 trial)

paclitaxel (taxol) (4 trials)

sodium chloride (2 trials)

sorafenib (nexavar) (3 trials)

spironolactone (aldactone) (1 trial)

thienoyridine (3 trials)

warfarin (coumadin) (3 trials)

ytttrium-90 microspheres (1 trial)

Drugs in Phase 2 Trials (21)

Key: Boston Scientific Corporation (0) Acquired (21)

bevacizumab (avastin) (1 trial)

bgc20-0582 (1 trial)

bgc20-1531 (1 trial)

brivudine phosphoramidate (1 trial)

caricotamide (1 trial)

cetuximab (erbitux) (2 trials)

cisplatin (platinol) (1 trial)

covaccine (2 trials)

digoxin immune fab (ovine) (DigiFab) (1 trial)

doxorubicin (Doxil) (3 trials)

durvalumab (imfinzi) (2 trials)

fluorouracil (efudex) (5 trials)

glucagon-like peptide-1 (1 trial)

glucarpidase (voraxaze) (8 trials)

irinotecan (Camptosar) (5 trials)

lactose (1 trial)

leucovorin (5 trials)

oxaliplatin (eloxatin) (3 trials)

pembrolizumab (keytruda) (2 trials)

pleneva (1 trial)

tremelimumab (Imjudo) (1 trial)

Drugs in Phase 1 Trials (7)

Key: Boston Scientific Corporation (0) Acquired (7)

68ga-maa (1 trial)

cm3.1-ac100 (3 trials)

methotrexate (1 trial)

naltrexone (revia) (1 trial)

survivin-peptide double loaded dendritic cells (1 trial)

tc 99m maa (1 trial)

vandetanib (caprelsa) (1 trial)

Drugs in Other Trials (6)

dark chocolate (1 trial)

dofetilide (tikosyn) (1 trial)

flecainide (tambocor) (1 trial)

rivaroxaban (xarelto) (1 trial)

(r)-propafenone (1 trial)

sotalol (betapace) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Coronary Syndrome (Phase 4)

Arterial Occlusive Diseases (Phase 3)

Atherosclerosis (Phase 3)

Atrial Fibrillation (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Heart Diseases (Phase 4)

Infarction (Phase 4)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Peripheral Arterial Disease (Phase 3)

Plaque, Atherosclerotic (Phase 3)

Postphlebitic Syndrome (Phase 3)

Postthrombotic Syndrome (Phase 3)

ST Elevation Myocardial Infarction (Phase 3)

Syndrome (Phase 4)

Thromboembolism (Phase 3)

Thrombosis (Phase 3)

Venous Thromboembolism (Phase 3)

Venous Thrombosis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 84
# of Trial APIs: 59